Stockreport

LENZ Therapeutics (LENZ) Is Down 7.1% After VIZZ Middle East Deal And Early Launch Data - Has The Bull Case Changed? [Yahoo! Finance]

LENZ Therapeutics, Inc.  (LENZ) 
PDF FDA-approved aceclidine-based eye drop for presbyopia, across key Middle Eastern markets including the UAE, Saudi Arabia, and Qatar. This deal, alongside early US laun [Read more]